John Duncan Higgons, Director at Jounce Therapeutics, Inc. (JNCE), sold 1,500 shares at $8.11 ($12K) on 2020-01-06, disclosed to the SEC on 2020-01-08.
Scheduled sale ($12k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| Filing → |
| JNCE | SELL | 2021-02-18 | $2K | — | Filing → |
| JNCE | SELL | 2021-01-22 | $20K | — | Filing → |
| JNCE | BUY | 2017-02-02 | $107K | — | Filing → |